Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy

Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin. Cancer Res., 20, 5064, 10.1158/1078-0432.CCR-13-3271 Lim, 2016, Pembrolizumab for the treatment of non-small cell lung cancer, Expert Opin. Biol. Ther., 16, 397, 10.1517/14712598.2016.1145652 Lloyd, 2013, Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies, Front. Immunol., 4, 221, 10.3389/fimmu.2013.00221 Su, 2016, CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients, Sci. Rep., 6, 20070, 10.1038/srep20070 Su, 2017, CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer, Oncoimmunology, 6, e1249558, 10.1080/2162402X.2016.1249558 Iizasa, 2012, Epstein-Barr Virus (EBV)-associated gastric carcinoma, Viruses, 4, 3420, 10.3390/v4123420 Okugawa, 2004, Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide, Oncol. Rep., 12, 725 Rosenberg, 2008, Overcoming obstacles to the effective immunotherapy of human cancer, Proc. Natl. Acad. Sci U.S.A., 105, 12643, 10.1073/pnas.0806877105 Klein, 1976, Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia, Int. J. Cancer, 18, 421, 10.1002/ijc.2910180405 Butler, 2007, Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell, Clin. Cancer Res., 13, 1857, 10.1158/1078-0432.CCR-06-1905 Sluijter, 2010, 4–1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes, Clin. Immunol., 137, 221, 10.1016/j.clim.2010.07.009 Watts, 1999, T cell co-stimulatory molecules other than CD28, Curr. Opin. Immunol., 11, 286, 10.1016/S0952-7915(99)80046-6 Maus, 2002, Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB, Nat. Biotechnol., 20, 143, 10.1038/nbt0202-143 Butler, 2014, Human cell-based artificial antigen-presenting cells for cancer immunotherapy, Immunol. Rev., 257, 191, 10.1111/imr.12129 Pollok, 1993, Inducible T cell antigen 4-1BB. Analysis of expression and function, J. Immunol., 150, 771, 10.4049/jimmunol.150.3.771 Hurtado, 1997, Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death, J. Immunol., 158, 2600, 10.4049/jimmunol.158.6.2600 Dharmadhikari, 2016, CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses, Oncoimmunology, 5, e1113367, 10.1080/2162402X.2015.1113367 Sussman, 2004, Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion, Cancer Res., 64, 9124, 10.1158/0008-5472.CAN-03-0376 Wang, 2004, Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells, J. Transl. Med., 2, 41, 10.1186/1479-5876-2-41 Friedman, 2011, Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement, J. Immunother., 34, 651, 10.1097/CJI.0b013e31823284c3 Teschner, 2011, In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads, Scand. J. Immunol., 74, 155, 10.1111/j.1365-3083.2011.02564.x Alvarez-Fernandez, 2016, A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy, J. Transl. Med., 14, 214, 10.1186/s12967-016-0973-y Ferrari-Lacraz, 2008, IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes, Int. Immunol., 20, 1009, 10.1093/intimm/dxn059 Li, 2005, IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response, J. Immunol., 175, 2261, 10.4049/jimmunol.175.4.2261 Moroz, 2004, IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21, J. Immunol., 173, 900, 10.4049/jimmunol.173.2.900 Di Carlo, 2004, IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice, J. Immunol., 172, 1540, 10.4049/jimmunol.172.3.1540 Markley, 2010, IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice, Blood, 115, 3508, 10.1182/blood-2009-09-241398 Li, 2008, IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes, Blood, 111, 229, 10.1182/blood-2007-05-089375 Zeng, 2005, Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function, J. Exp. Med., 201, 139, 10.1084/jem.20041057 Liu, 2007, IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells, Int. Immunol., 19, 1213, 10.1093/intimm/dxm093 Orio, 2015, Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation, Cytotherapy, 17, 496, 10.1016/j.jcyt.2014.12.009 Alves, 2005, IL-21 sustains CD28 expression on IL-15-activated human Naive CD8+ T cells, J. Immunol., 175, 755, 10.4049/jimmunol.175.2.755 Weber, 2010, Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade, Semin. Oncol., 37, 430, 10.1053/j.seminoncol.2010.09.005 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690 Lipson, 2013, Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody, Clin. Cancer Res., 19, 462, 10.1158/1078-0432.CCR-12-2625 Tang, 2014, T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo, J. Biomed. Res., 28, 468, 10.7555/JBR.28.20140066 Kebriaei, 2016, Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J. Clin. Invest., 126, 3363, 10.1172/JCI86721 John, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin. Cancer Res., 19, 5636, 10.1158/1078-0432.CCR-13-0458 Tanoue, 2017, Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors, Cancer Res., 77, 2040, 10.1158/0008-5472.CAN-16-1577 Besser, 2010, Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients, Clin. Cancer Res., 16, 2646, 10.1158/1078-0432.CCR-10-0041 Radvanyi, 2012, Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients, Clin. Cancer Res., 18, 6758, 10.1158/1078-0432.CCR-12-1177 Dudley, 2013, Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma, J. Clin. Oncol., 31, 2152, 10.1200/JCO.2012.46.6441 Olson, 2013, Effector-like CD8(+) T cells in the memory population mediate potent protective immunity, Immunity, 38, 1250, 10.1016/j.immuni.2013.05.009 Chacon, 2013, Co-Stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy, PLoS One, 8, e60031, 10.1371/journal.pone.0060031 Wang, 2016, Augmented CD3(+)CD8(+) and CD3(+)CD56(-) cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor, Cytotherapy, 18, 581, 10.1016/j.jcyt.2015.11.021 Zhang, 2007, 4–1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy, J. Immunol., 179, 4910, 10.4049/jimmunol.179.7.4910 Bukczynski, 2004, Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses, Proc. Natl. Acad. Sci. U.S.A., 101, 1291, 10.1073/pnas.0306567101 Li, 2010, MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro, J. Immunol., 184, 452, 10.4049/jimmunol.0901101 Bullock, 2017, Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer, Curr. Opin. Immunol., 45, 82, 10.1016/j.coi.2017.02.001 Esensten, 2016, CD28 costimulation: from mechanism to therapy, Immunity, 44, 973, 10.1016/j.immuni.2016.04.020 Gharibi, 2016, Biological effects of IL-21 on different immune cells and its role in autoimmune diseases, Immunobiology, 221, 357, 10.1016/j.imbio.2015.09.021 Hinrichs, 2008, IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy, Blood, 111, 5326, 10.1182/blood-2007-09-113050 Huang, 2005, Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression, J. Immunother., 28, 258, 10.1097/01.cji.0000158855.92792.7a